

Tateaki Naito

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9118982/tateaki-naito-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

197
papers

4,561
citations

32
h-index

61
g-index

231
ext. papers

5,314
ext. citations

3.4
avg, IF

5.03
L-index

#	Paper	IF	Citations
197	Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. <i>Respirology</i> , 2008 , 13, 452-60	3.6	555
196	Cumulative incidence of and predictive factors for lung cancer in IPF. <i>Respirology</i> , 2009 , 14, 723-8	3.6	189
195	Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. <i>Respiratory Medicine</i> , 2009 , 103, 846-53	4.6	164
194	Prognostic impact of circulating tumor cells in patients with small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 512-9	8.9	135
193	Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. <i>PLoS ONE</i> , 2013 , 8, e67466	3.7	131
192	The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1242-6	8.9	127
191	Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. <i>Radiology</i> , 2009 , 252, 247-54	20.5	124
190	Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3746-53	2.2	123
189	Interstitial lung diseases associated with amyopathic dermatomyositis. <i>European Respiratory Journal</i> , 2006 , 28, 1005-12	13.6	109
188	Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. <i>Cancer Science</i> , 2011 , 102, 1032-7	6.9	99
187	Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 460-5	8.9	95
186	Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. <i>Supportive Care in Cancer</i> , 2015 , 23, 1699-708	3.9	91
185	Microcavity array system for size-based enrichment of circulating tumor cells from the blood of patients with small-cell lung cancer. <i>Analytical Chemistry</i> , 2013 , 85, 5692-8	7.8	80
184	Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). <i>Cancer</i> , 2018 , 124, 606-616	6.4	75
183	Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 891-9	3.5	71
182	Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. <i>Lung Cancer</i> , 2011 , 74, 457-61	5.9	68
181	Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 171, 707-13	10.2	66

180	Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure. <i>Cancer Science</i> , 2016 , 107, 1001-5	6.9	66
179	Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. <i>Lung Cancer</i> , 2010 , 67, 194-7	5.9	65
178	Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019 , 10, 73-83	10.3	57
177	Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012 , 30, 2352-63	4.3	52
176	LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. <i>American Journal of Translational Research (discontinued)</i> , 2011 , 3, 468-78	3	49
175	Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 521-6	3.5	48
174	Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 68, 99-104	5.9	46
173	Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. <i>Lung Cancer</i> , 2010 , 68, 438-45	5.9	45
172	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. <i>Cancer</i> , 2019 , 125, 4294-4302	6.4	42
171	Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. <i>BMC Cancer</i> , 2017 , 17, 571	4.8	39
170	Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. <i>BMC Cancer</i> , 2013 , 13, 354	4.8	35
169	Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. <i>BMC Cancer</i> , 2017 , 17, 800	4.8	34
168	The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who received concurrent chemoradiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 144-7	2.7	33
167	Biologic correlates of 18 F-FDG uptake on PET in pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2011 , 71, 144-50	5.9	33
166	Long-term survivors of more than 5 years in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 67, 120-3	5.9	33
165	High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy. <i>Annals of Oncology</i> , 2017 , 28, 669-670	10.3	31
164	Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. <i>BMC Cancer</i> , 2016 , 16, 864	4.8	31
163	Multiplexed molecular profiling of lung cancer using pleural effusion. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1048-1052	8.9	31

162	A validation and potential modification of the pneumonia severity index in elderly patients with community-acquired pneumonia. <i>Journal of the American Geriatrics Society</i> , 2006 , 54, 1212-9	5.6	31
161	L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. <i>Anticancer Research</i> , 2011 , 31, 4075-82	2.3	30
160	Molecular profiling of small cell lung cancer in a Japanese cohort. <i>Lung Cancer</i> , 2014 , 84, 139-44	5.9	29
159	Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. <i>Anticancer Research</i> , 2012 , 32, 1103-6	2.3	29
158	Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 432-3	8.9	28
157	Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. <i>Annals of Oncology</i> , 2014 , 25, 1948-1953	10.3	28
156	Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, e247-e252	4.9	28
155	Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3741-3747	3.7	27
154	The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. <i>Annals of Oncology</i> , 2013 , 24, 1653-9	10.3	26
153	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. <i>Annals of Thoracic Medicine</i> , 2015 , 10, 61-6	2.2	26
152	Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2015 , 15, 989	4.8	25
151	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. <i>Cancer Science</i> , 2018 , 109, 2539-2548	6.9	24
150	Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. <i>BMC Cancer</i> , 2014 , 14, 18	4.8	24
149	The role of β -tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. <i>International Journal of Clinical Oncology</i> , 2013 , 18, 371-9	4.2	24
148	Promotion of Behavioral Change and the Impact on Quality of Life in Elderly Patients with Advanced Cancer: A Physical Activity Intervention of the Multimodal Nutrition and Exercise Treatment for Advanced Cancer Program. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018 , 5, 383-390	2.2	24
147	Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 604-613	4	23
146	Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. <i>Lung Cancer</i> , 2012 , 76, 439-44	5.9	23
145	¹⁸ F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. <i>Annals of Nuclear Medicine</i> , 2011 , 25, 247-53	2.5	23

144	Lung dendritic cells have a potent capability to induce production of immunoglobulin A. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008 , 38, 161-7	5.7	23
143	A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. <i>BMC Cancer</i> , 2019 , 19, 528	4.8	22
142	Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. <i>Neoplasma</i> , 2014 , 61, 233-40	3.3	22
141	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. <i>International Journal of Clinical Oncology</i> , 2018 , 23, 1052-1059	4.2	20
140	Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. <i>Anticancer Research</i> , 2011 , 31, 4519-23	2.3	19
139	Biological correlation of 18 F-FDG uptake on PET in pulmonary neuroendocrine tumors. <i>Anticancer Research</i> , 2013 , 33, 4219-28	2.3	19
138	Identification of actionable mutations in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014 , 86, 35-40	5.9	18
137	Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. <i>Lung Cancer</i> , 2011 , 74, 419-25	5.9	18
136	Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy. <i>Oncotarget</i> , 2018 , 9, 17664-17674	3.3	18
135	Skeletal muscle loss and prognosis of breast cancer patients. <i>Supportive Care in Cancer</i> , 2017 , 25, 2221-2227	3.7	17
134	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2017 , 22, 690-697	4.2	17
133	Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity. <i>Lung Cancer</i> , 2016 , 99, 151-4	5.9	17
132	Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. <i>Oncology Reports</i> , 2011 , 26, 931-7	3.5	17
131	Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review. <i>Therapeutics and Clinical Risk Management</i> , 2019 , 15, 1253-1266	2.9	17
130	ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature. <i>BMC Cancer</i> , 2017 , 17, 471	4.8	16
129	Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib. <i>Journal of Clinical Oncology</i> , 2013 , 31, e417-9	2.2	16
128	Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer. <i>Respirology</i> , 2017 , 22, 1379-1385	3.6	15
127	18 F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: a clinicopathological study. <i>European Journal of Radiology</i> , 2012 , 81, 2423-9	4.7	15

126	Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence. <i>Anticancer Research</i> , 2011 , 31, 3775-82	2.3	15
125	Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017 , 106, 138-144	5.9	14
124	Evaluation of the True Endpoint of Clinical Trials for Cancer Cachexia. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2019 , 6, 227-233	2.2	14
123	Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 28-32	2.7	14
122	Impact of Cancer Cachexia on Hospitalization-associated Physical Inactivity in Elderly Patients with Advanced Non-small-cell Lung Cancer. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018 , 5, 377-382	2.2	14
121	Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy. <i>Journal of Cancer</i> , 2018 , 9, 2054-2060	4.5	14
120	Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib. <i>Anticancer Research</i> , 2009 , 29, 2747-51	2.3	14
119	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. <i>Medical Oncology</i> , 2014 , 31, 88	3.7	13
118	Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β -III-tubulin in thymic epithelial tumors. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 606-13	8.9	13
117	Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2010 , 15, 161-5	4.2	13
116	Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. <i>Anticancer Research</i> , 2014 , 34, 1975-81	2.3	13
115	A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. <i>Japanese Journal of Clinical Oncology</i> , 2017 , 47, 840-843	2.8	12
114	CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma. <i>Tumor Biology</i> , 2018 , 40, 1010428318760420	2.9	12
113	ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease. <i>Lung Cancer</i> , 2018 , 121, 48-53	5.9	12
112	Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens. <i>International Journal of Clinical Oncology</i> , 2014 , 19, 63-7	4.2	12
111	Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2013 , 14, 440-5	4.9	12
110	N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. <i>International Journal of Clinical Oncology</i> , 2010 , 15, 484-8	4.2	12
109	Intestinal metastasis from non-small-cell lung cancer initially detected by 18 F-fluorodeoxyglucose positron emission tomography. <i>Japanese Journal of Radiology</i> , 2010 , 28, 684-7	2.9	12

108	Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer. <i>Annals of Nuclear Medicine</i> , 2010 , 24, 697-705	2.5	12
107	CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. <i>Oncology Reports</i> , 2010 , 24, 861-7	3.5	12
106	The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 1229-1237	3.5	11
105	Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, e405-e414	4.9	11
104	Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 859-866	2.8	11
103	Cardiac Dysfunction Caused by Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e159-e160	8.9	11
102	Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study. <i>Japanese Journal of Clinical Oncology</i> , 2009 , 39, 158-62	2.8	11
101	Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer. <i>Cancer Science</i> , 2016 , 107, 1018-21	6.9	11
100	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJTO685151 Study. <i>Clinical Lung Cancer</i> , 2017 , 18, 719-723	4.9	10
99	The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. <i>International Journal of Clinical Oncology</i> , 2015 , 20, 668-73	4.2	10
98	The effects of advanced age and serum ß ₂ -microglobulin on docetaxel unbound exposure and dose-limiting toxicity in cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2416-2425	3.8	10
97	S-1 treatment for chemorefractory thymic carcinoma. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 1076	8.9	10
96	Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study. <i>PLoS ONE</i> , 2019 , 14, e0210074	3.7	10
95	MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer. <i>Pathology and Oncology Research</i> , 2012 , 18, 439-47	2.6	9
94	Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 128, 152-157	5.9	9
93	Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma. <i>Molecular and Clinical Oncology</i> , 2017 , 6, 718-722	1.6	8
92	PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 617-622	2.8	8
91	Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 609-614	3.5	8

90	Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine. <i>Chemotherapy</i> , 2013 , 59, 307-13	3.2	8
89	Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. <i>Cancer Science</i> , 2013 , 104, 1039-44	6.9	8
88	Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression. <i>Lung Cancer</i> , 2021 , 151, 60-68	5.9	8
87	Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021 , 10, 247-256	4.8	8
86	Disease flare after gefitinib discontinuation. <i>Respiratory Investigation</i> , 2015 , 53, 68-72	3.4	7
85	Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitary lesions. <i>Respiratory Investigation</i> , 2014 , 52, 184-9	3.4	7
84	Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 859-65	3.5	7
83	Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer. <i>Anticancer Research</i> , 2012 , 32, 675-80	2.3	7
82	Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy. <i>Radiology and Oncology</i> , 2015 , 49, 409-15	3.8	6
81	Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more. <i>Lung Cancer</i> , 2011 , 71, 173-7	5.9	6
80	Reactive Legionella pneumophila arthritis diagnosed by polymerase chain reaction. <i>Rheumatology International</i> , 2007 , 27, 415-6	3.6	6
79	Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy. <i>Molecular and Clinical Oncology</i> , 2016 , 5, 575-578	1.6	6
78	Gefitinib-Induced Cardiomyopathy in Epidermal Growth Receptor-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e207-e208	8.9	6
77	Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis. <i>Anticancer Research</i> , 2012 , 32, 1811-6	2.3	6
76	Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation. <i>Anticancer Research</i> , 2013 , 33, 3279-84	2.3	6
75	Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status. <i>Nutrition and Cancer</i> , 2019 , 71, 767-771	2.8	5
74	Primary malignant melanoma of the trachea: A case report. <i>Oncology Letters</i> , 2015 , 9, 657-660	2.6	5
73	The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients. <i>Investigational New Drugs</i> , 2015 , 33, 755-60	4.3	5

72	Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. <i>SpringerPlus</i> , 2015 , 4, 152		5
71	Characteristics of cellular composition in malignant pericardial effusion and its association with the clinical course of carcinomatous pericarditis. <i>Japanese Journal of Clinical Oncology</i> , 2018 , 48, 291-294	2.8	5
70	Efficacy of daikenchuto, a traditional Japanese Kampo medicine, for postoperative intestinal dysfunction in patients with gastrointestinal cancers: meta-analysis. <i>International Journal of Clinical Oncology</i> , 2019 , 24, 1385-1396	4.2	5
69	Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. <i>Respiratory Investigation</i> , 2014 , 52, 101-6	3.4	5
68	Perianal metastasis of non-small cell lung cancer. <i>Internal Medicine</i> , 2014 , 53, 1149-52	1.1	5
67	18 F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms. <i>Oncology Reports</i> , 2014 , 31, 209-15	3.5	5
66	Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan. <i>Respiratory Investigation</i> , 2012 , 50, 157-61	3.4	5
65	Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery. <i>Molecular and Clinical Oncology</i> , 2013 , 1, 949-952	1.6	5
64	Characterization of tumour mutation burden in patients with non-small cell lung cancer and interstitial lung disease. <i>Respirology</i> , 2020 , 25, 850-854	3.6	5
63	Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100020	1.4	5
62	Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2020 , 38, 1612-1617	4.3	4
61	Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer. <i>In Vivo</i> , 2019 , 33, 2229-2234	2.3	4
60	Prognostic impact of 18 F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy. <i>Respiratory Investigation</i> , 2014 , 52, 121-8	3.4	4
59	Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 1777-82	4	4
58	18 F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?. <i>Neoplasia</i> , 2012 , 59, 257-63	3.3	4
57	Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older. <i>Japanese Journal of Clinical Oncology</i> , 2013 , 43, 176-83	2.8	4
56	Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6. <i>International Journal of Clinical Oncology</i> , 2009 , 14, 534-6	4.2	4
55	Efficacy of a consensus protocol therapy in adults with acute, severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2003 , 90, 331-7	3.2	4

54	Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities. <i>Radiation Oncology</i> , 2021 , 16, 52	4.2	4
53	Development of home-based resistance training for older patients with advanced cancer: The exercise component of the nutrition and exercise treatment for advanced cancer program. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 952-955	3.6	4
52	Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. <i>Investigational New Drugs</i> , 2021 , 39, 571-577	4.3	4
51	Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing. <i>Clinical Lung Cancer</i> , 2017 , 18, 519-526.e1	4.9	3
50	Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2019 , 39, 1463-1468	2.3	3
49	Acquired immunodeficiency associated with thymoma: a case report. <i>BMC Cancer</i> , 2019 , 19, 762	4.8	3
48	Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1493-8	3.5	3
47	Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2014 , 86, 339-43	5.9	3
46	Thenar muscle metastasis as recurrence of pulmonary squamous cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011 , 7, 15-6	1.9	3
45	Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. <i>Investigational New Drugs</i> , 2021 , 39, 1716-1723	4.3	3
44	Proposing synchronous oligometastatic non-small-cell lung cancer based on progression after first-line systemic therapy. <i>Cancer Science</i> , 2021 , 112, 359-368	6.9	3
43	Crizotinib-induced simultaneous multiple cardiac toxicities. <i>Investigational New Drugs</i> , 2018 , 36, 949-951.4.3	4.3	2
42	Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. <i>British Journal of Cancer</i> , 2018 , 118, 1571-1579	8.7	2
41	Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein. <i>Investigational New Drugs</i> , 2019 , 37, 184-187	4.3	2
40	Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer. <i>Journal of Neuro-Oncology</i> , 2017 , 135, 299-306	4.8	2
39	Well-differentiated hepatocellular carcinoma showing intrahepatic neural invasion: autopsied case. <i>Japanese Journal of Clinical Oncology</i> , 1991 , 21, 143-6	2.8	2
38	Identification of actionable mutations in surgically resected tumor specimens from Japanese patients with non-small cell lung cancer by ultra-deep targeted sequencing.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7572-7572	2.2	2
37	Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation. <i>Investigational New Drugs</i> , 2020 , 38, 194-201	4.3	2

36	Management of anorexia prevents skeletal muscle wasting during cisplatin-based chemotherapy for thoracic malignancies. <i>JCSM Clinical Reports</i> , 2020 , 5, 8-15	1.5	2
35	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.. <i>Cancer</i> , 2022 ,	6.4	2
34	Barriers in Nursing Practice in Cancer Cachexia: A Scoping Review. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021 , 8, 498-507	2.2	2
33	Efficacy of second-line chemotherapy in poor-risk patients with refractory-relapsed small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018 , 48, 822-826	2.8	1
32	Tracheal granuloma 7 years after extubation. <i>Respirology Case Reports</i> , 2017 , 5, e00252	0.9	1
31	Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014 , 5, 121-5	3.2	1
30	Papillary squamous cell carcinoma of the trachea associated with human papillomavirus-18 infection. <i>Internal Medicine</i> , 2013 , 52, 2785-8	1.1	1
29	Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors. <i>Oncology Letters</i> , 2011 , 2, 1059-1064	2.6	1
28	Changes in TROP2 expression in lung cancer patients receiving anticancer treatments.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14732-e14732	2.2	1
27	The impact of steroid use on efficacy of immunotherapy among patients with lung cancer who have developed immune-related adverse events.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20583-e20583	2.2	1
26	Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis. <i>Investigational New Drugs</i> , 2021 , 1	4.3	1
25	Clinical impact of walking capacity on the risk of disability and hospitalizations among elderly patients with advanced lung cancer. <i>Supportive Care in Cancer</i> , 2021 , 29, 3961-3970	3.9	1
24	Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	1
23	Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation. <i>Cancer Medicine</i> , 2021 , 10, 7503-7513	4.8	1
22	Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	1
21	Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 659-669	4.2	1
20	Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 605-614	3.5	0
19	Lymphangitis carcinomatosa as a potential predictor for a response to gefitinib. <i>Clinical Oncology</i> , 2006 , 18, 573-4	2.8	0

18	Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2021 , 21, 1247	4.8	○
17	Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage small-cell lung cancer.. <i>Lung Cancer</i> , 2021 , 164, 39-45	5.9	○
16	Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2021 , 1	4.3	○
15	Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 1736-1743	2.8	○
14	Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer. <i>Journal of Multidisciplinary Healthcare</i> , 2021 , 14, 1521-1532	2.8	○
13	Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. <i>Investigational New Drugs</i> , 2021 , 39, 1732-1741	4.3	○
12	Foreign Body Impaction in the Esophagus. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 923	6.4	
11	Development of the Early Nutritional Intervention for Elderly Patients with Advanced Cancer: Details of Nutritional Intervention in the Multimodal NEXTAC-ONE Program. <i>Palliative Care Research</i> , 2020 , 15, 71-80	0.1	
10	Barriers in Nursing Practice in Cancer Cachexia: A Scoping Review. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021 , 8, 498-507	2.2	
9	A randomized phase II study of the nutritional and exercise treatment for the elderly patients with advanced non-small cell lung or pancreatic cancer: The NEXTAC-TWO study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS10131-TPS10131	2.2	
8	Optimal treatment sequence for untreated EGFR-mutant NSCLC with brain metastases.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e14021-e14021	2.2	
7	Impact of baseline number of metastases on the efficacy of PD-1 inhibitor monotherapy for non-small cell lung cancer with high PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20551-e20551	2.2	
6	Multimutational profiling of rebiopsy samples from NSCLC developing acquired resistance to EGFR-TKI in Japanese patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19032-e19032	2.2	
5	Long-term clinical outcomes of ALK inhibitors in patients with ALK-positive advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20542-e20542	2.2	
4	Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21113-e21113	2.2	
3	Days Spent at Home near the End of Life in Japanese Elderly Patients with Lung Cancer: Analysis of A Prospective Study. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021 , 8, 228-236	2.2	
2	A Patient with a Massive Single Cardiac Metastasis of Lung Adenocarcinoma, Diagnosed via a Biopsy. <i>Internal Medicine</i> , 2018 , 57, 1637-1640	1.1	
1	Development of Low-intensity Home-based Resistance Training for Elderly Patients with Advanced Cancer: The Exercise Component of the NEXTAC Program. <i>Palliative Care Research</i> , 2018 , 13, 373-381	0.1	

